A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI's) lamivudine [(-)2'-deoxy-3'thiacytidine, 3tc], zidovudine (ZDV) and 1592U89 [abacavir].

Trial Profile

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI's) lamivudine [(-)2'-deoxy-3'thiacytidine, 3tc], zidovudine (ZDV) and 1592U89 [abacavir].

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2009

At a glance

  • Drugs Nelfinavir (Primary) ; Abacavir; Lamivudine; Zidovudine
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PENTA-5
  • Most Recent Events

    • 23 Jul 2009 Actual end date (31 Jul 1999) added as reported by ISRCTN: Current Controlled Trials.
    • 23 Jul 2009 Additional lead trial centres, planned patient number (120) and actual initiation date (23 Jan 1998) added as reported by ISRCTN: Current Controlled Trials.
    • 23 Jul 2009 Planned patient number (120) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top